Thompson A J, Hobart J C
Institute of Neurology, London, UK.
J Neurol. 1998 Apr;245(4):189-96. doi: 10.1007/s004150050204.
Attempting to measure the impact of multiple sclerosis (MS) on the individuals patients has become a major issue stimulated by both the emergence of new therapeutic agents and the increasing demand to incorporate the patient's perspective. Disability has been the main focus. Recently, new disability scales have been developed and generic scales evaluated in an attempt to replace or complement the constantly used and much criticized Expanded Disability Status Scale (EDSS). There is, however, the growing realization that it is important to incorporate broader aspects of disease input such as are contained within the concepts of health-related quality of life. Current scales in this area are limited in either their scientific soundness and/or clinical usefulness, and it may be appropriate to consider the development of a new MS-specific measure of disease impact for use in clinical trials.
试图衡量多发性硬化症(MS)对个体患者的影响已成为一个重大问题,这是由新治疗药物的出现以及纳入患者观点的需求不断增加所推动的。残疾一直是主要关注点。最近,新的残疾量表已经开发出来,通用量表也经过了评估,试图取代或补充一直使用且备受批评的扩展残疾状态量表(EDSS)。然而,人们越来越意识到纳入疾病影响的更广泛方面很重要,比如健康相关生活质量概念中所包含的那些方面。该领域目前的量表在科学合理性和/或临床实用性方面都存在局限性,或许考虑开发一种新的针对MS的疾病影响测量方法用于临床试验是合适的。